Phase I dose-escalation study of the tolerability and pharmacokinetics of a weekly 24h infusion of rigosertib in patients with advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Onconova Therapeutics
- 23 Feb 2012 Actual initiation date (June 2006), additional lead investigator (Sridhar Mani) and actual patient no 42 added as reported by ClinicalTrials.gov.
- 23 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 23 Feb 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.